Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 ye ...

Currently available fixed combination topicals have robust efficacy, and the recently approved cream formulations of tapinarof and roflumilast appear to have efficacy that may be higher than ...

Zoryve (roflumilast, Arcutis) cream 0.05% is a once-daily, next-generation phosphodiesterase-4 inhibitor that offers a nonsteroidal option for children and their caregivers. The FDA has accepted ...

Zoryve (roflumilast) is a prescription drug that’s used to treat plaque psoriasis, atopic dermatitis, and seborrheic dermatitis in adults and certain children. Zoryve comes as a topical cream or ...

Senores Pharmaceuticals through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPL) has signed an agreement to acquire the US FDA approved Abbreviated New Drug Application (ANDA) for ...

Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) ...

Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024; driven by strong portfolio demand growth ...

Senores Pharmaceuticals Limited announced the acquisition of US marketing rights for Roflumilast tablets through its American subsidiary. The deal with Breckenridge Pharmaceutical, Inc., a ...

One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intolerance, and/or contraindications to topical ...

Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according to a study published online Feb. 20 in Pediatric Dermatology.